Sluiten
![01 2023 01 16 BDD Poster guselkumab Ra S](/files/Posters/BDD-2023/images/01-2023-01-16-BDD-Poster_guselkumab_RaS.jpg)
Exploring the exposure-response relationship of Guselkumab in chronic plaque Psoriasis: Preliminary results
Rani Soenen
![02 2023 01 11 BDD Poster Lisa S portrait](/files/Posters/BDD-2023/images/02__-2023-01-11-BDD-Poster_LisaS_portrait.jpg)
Blocking Interleukin-17 in Psoriasis: Real-world experience from the PsoPlus cohort
Lisa Schots
![03 Prevalence of comorbidities in the UZ Leuven psoriasis cohort](/files/Posters/BDD-2023/images/03__-Prevalence-of-comorbidities-in-the-UZ-Leuven-psoriasis-cohort.jpg)
Psoriasis in the Belgian population: Prevalence of comorbidities
Heleen Cokelaere
Tom Hillary
![04 BDD2023 Poster 4](/files/Posters/BDD-2023/images/04__-BDD2023-Poster-4.jpg)
Nectin-4-directed oncologic therapies, what to expect as a dermatologist?
Evelyn Meulewaeter
Linda Temmerman
![05 BDD2023 Poster PGD UZL](/files/Posters/BDD-2023/images/05__-BDD2023_Poster_PGD_UZL.jpg)
The impact of the COVID-19 pandemic on the incidence and thickness of cutaneous melanoma in Belgium
P.G. Demaerel
![06 Poster BDD](/files/Posters/BDD-2023/images/06__-Poster-BDD.jpg)
A cohort study of older adults receiving Mohs micrographic surgery for a facial basal cell carcinoma: should we waive MMS in certain patients?
Laura Van Coile
![07 Poster BDD190123](/files/Posters/BDD-2023/images/07__-PosterBDD190123.jpg)
Vitamin D receptor expression in cutaneous melanoma tissue: Prognostic properties and influencing factors
Julie De Smedt
![08 poster BDD2023 08](/files/Posters/BDD-2023/images/08__-posterBDD2023-08.jpg)
Acute pancreatitis induced by topical Isotretinoin, an unprecedented association
Thomas Damsin
![09 BDD poster Prognostic Value Disease Activity Signs Vitiligo n9](/files/Posters/BDD-2023/images/09__-BDD_poster_PrognosticValueDiseaseActivitySignsVitiligo_n9.jpg)
Prognostic value of the Vitiligo disease activity signs
Liesbeth Delbaere
![10 BDD 2023 POETYK BSA s PG Ax BSA Encore Poster Bristol Myers Squibb Lambert](/files/Posters/BDD-2023/images/10__-BDD-2023_POETYK-BSA-sPGAxBSA-Encore-Poster_Bristol-Myers-Squibb_Lambert.jpg)
Deucravacitinib, an oral, selective, Allosteric Tyrosine Kinase 2 Inhibitor, versus placebo and Apremilast in moderate to severe plaque Psoriasis: Analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials
Jo Lambert
![11 Key secondary endpoints at Month 12 3rd Interim BDD 2023 Final draft 18 Jan2023](/files/Posters/BDD-2023/images/11__-Key-secondary-endpoints-at-Month-12-3rd-Interim_BDD-2023_Final-draft_18Jan2023.jpg)
Initial report on the month 12 results from the Psoriasis Study of Health Outcomes (PSoHO) for patients with moderate-to-severe psoriasis treated with biologics in the real-world setting
L. Ghys
![12 Multiple CBA global Ps O improv in all 3 measures BDD 2023 18 Jan2023](/files/Posters/BDD-2023/images/12__-Multiple-CBA-global-PsO-improv-in-all-3-measures_BDD-2023_18Jan2023.jpg)
Ixekizumab demonstrates comprehensive Psoriasis clearance in patients with moderate-to-severe Psoriasis with scalp, nail, and/or palmoplantar involvement: UNCOVER-1, -2 trials through 5 years
L. Ghys
![13 Poster BDD 2023 nr13 REDISCOVER Final Version Hillary et al](/files/Posters/BDD-2023/images/13__-Poster-BDD-2023-nr13_REDISCOVER_Final-Version_Hillary-et-al.jpg)
Disease severity and implementation of the Belgian T2T guidelines in moderate-to-severe plaque Psoriasis: Results from the Belgian REDISCOVER study
L.F.E Ghys
![14 Poster number 14 BDD 2023 JAHO JAIR Trajectories Final Draft 20 Jan2023](/files/Posters/BDD-2023/images/14__-Poster-number-14_BDD-2023_JAHO-JAIR-Trajectories_Final-Draft_20Jan2023.jpg)
Trajectories for scalp hair regrowth in patients with severe Alopecia Areata treated with Baricitinib
L. Ghys
![15 Poster number 15 BDD 2023 JAHN 2yr Qo L Final draft 20 Jan 2023](/files/Posters/BDD-2023/images/15__-Poster-number-15_BDD-2023_JAHN-2yr-QoL_Final-draft_20-Jan-2023.jpg)
Maintained improvement in patient rated outcomes with Baricitinib 4-mg in adults with moderate to severe Atopic Dermatitis who were treated for up to 104 weeks in randomised controlled trials
L. Ghys
![16 Poster number 16 BDD 2023 AD Annual Safety 2022 Final draft 20 Jan 2023](/files/Posters/BDD-2023/images/16__-Poster-number-16_BDD-2023_AD-Annual-Safety-2022_Final-draft_20-Jan-2023.jpg)
Safety of Baricitinib for the treatment of Atopic Dermatitis over a median of 1.6 and up to 3.9 years treatment: An updated integrated analysis of 8 clinical trials
L. Ghys
![17 BDD 2023 SUNNY Wk16 Poster 17](/files/Posters/BDD-2023/images/17__-BDD-2023_SUNNY-Wk16_Poster-17.jpg)
Secukinumab in moderate to severe Hidradenitis Suppurativa: Primary endpoint analysis from the SUNSHINE and SUNRISE phase 3 trials
Farida Benhadou